Weight development in patients treated with risperidone: a 5-year naturalistic study
Article first published online: 29 SEP 2006
Acta Psychiatrica Scandinavica
Volume 115, Issue 4, pages 277–285, April 2007
How to Cite
Neovius, M., Eberhard, J., Lindström, E. and Levander, S. (2007), Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatrica Scandinavica, 115: 277–285. doi: 10.1111/j.1600-0447.2006.00899.x
- Issue published online: 13 MAR 2007
- Article first published online: 29 SEP 2006
- Accepted for publication July 13, 2006
- body mass index;
Objective: To examine annual weight-development in a sample of 215 psychotic patients treated with risperidone over 5 years.
Method: Naturalistic longitudinal study.
Results: The sample was more obese than the general population at baseline, but also increased much more in mean body mass index over approximately the same time period, while patients off medication seemed to remain weight stable. Excessive weight gain (>7%) was experienced by 40.2% and was weakly associated with weight at baseline (β = −0.2%; P = 0.02), while independent of gender, symptoms, years of illness, prolactin levels and nicotine consumption. In patients with complete weight data (n = 87), approximately 72% (3.4 ± 8.3 kg) of the observed 5 years weight gain (4.7 ± 11.6 kg) had been accumulated after 2 years.
Conclusion: Antipsychotic drug treatment resulted in significant weight gain, which levelled off over time. Unfortunately, few significant predictors of adverse weight development could be identified, leaving little guidance for clinical decision making regarding this specific side-effect.